Alpha Cognition Inc (TSE:ACOG) has released an update.
Alpha Cognition Inc. has announced its year-end financials and provided updates, highlighting the FDA’s acceptance of its New Drug Application for ALPHA-1062, a potential Alzheimer’s treatment with an approval decision expected by July 2024. The company has also filed a new patent to extend ALPHA-1062’s protection till 2044 and successfully raised $8.45 million through a private placement to support its ongoing projects.
For further insights into TSE:ACOG stock, check out TipRanks’ Stock Analysis page.
